ClinicaleffectofZhenwu Decoction combined with intraperitoneal chemotherapy in the treatment of carcinomatous ascites of spleen and kidney yang deficiency type
LUO Jia-hua LIU Zhen-ha iLI Zeng-hui
Department of Oncology,Chenxinghai Hospital of Zhongshan City,Guangdong Province,Zhongshan 528415,China
Abstract：Objective To investigate the effect of Zhenwu Decoction combined with intraperitoneal chemotherapy in the treatment of carcinomatous ascites of spleen and kidney yang deficiency type.Methods The clinical data of 50 patients with carcinomatous ascites identified as spleen and kidney yang deficiency type treated in our hospital from January 2015 to January 2017 were analyzed.According to the different treatment methods,20 patients in the control group were treated with Cisplatin and Fluorouracil chemotherapy and the rest was classified into the observation group given Cisplatin and Fluorouracil chemotherapy plusing Zhenwu Decoction.T cell subsets,NK cells,clinical efficacy and the incidence of adverse reactions in the two groups were observed.Results The amount of CD4+,CD3+,CD8+,CD4+/CD8+and NK cells,and total clinical remission rate in the observation group were all higher than those in the control group and the incidence of adverse reactions such as hematological toxicity,gastrointestinal reaction,liver function damage,renal function damage,and mucosal ulcer was lower than that in the control group,with a statistical difference(P＜0.05).Conclusion Zhenwu Decoction combined with intraperitoneal chemotherapy in the treatment of carcinomatous ascites of spleenkidney yang deficiency type can improve the organismic immune function with a high remission rate and few adverse reactions,which is worthy of clinical application and promotion.
骆嘉华;刘振海;李增辉. 真武汤联合腹腔化疗治疗脾肾阳虚型癌性腹水的临床效果[J]. 中国当代医药, 2018, 25(11): 145-147.
LUO Jia-hua;LIU Zhen-hai;LI Zeng-hui. ClinicaleffectofZhenwu Decoction combined with intraperitoneal chemotherapy in the treatment of carcinomatous ascites of spleen and kidney yang deficiency type. 中国当代医药, 2018, 25(11): 145-147.
Yagi Y，Maeda T，Yoshim itsu Y，et al.A case of malignant peritoneal mesotheliom a diagnosed with laparoscopic biopsy[J].Gan To Kagaku Ryoho，2014，41（8）：995-997.
[4]
Tseng TC，Liu CJ，Yang HC.Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers[J].Gut，2015，64（2）：292-302.
Wen C，Duan Q，Zhang T，et al.Studies on assessment methods of malignant ascites residue and changes of verapamil concentration in intraperitoneal perfusion chemotherapy[J].Cancer Chemother Pharmacol，2014，74（3）：473-478.
[9]
Sehouli J，Pietzner K，Wim berger P，et al.Catum axomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer：results of the random ised phase Ⅲb CASIM AS study[J].Med Oncol，2014，31（8）：76.
Tsubam oto H，Takeuchi S，Ito K，et al.Feasibility and efficacy of intraperitoneal docetaxel adm inistration as salvage chem otherapy for malignant gynaecological ascites[J].J Obstet Gynaecol，2014，14（2）：1-5.
[12]
Singh N，Sifri CD，Silveira FP，et al.Cryptococcosis in patients with cirrhosis of the liver and posttransplant outcomes[J].Transplantation，2015，99（10）：2132-2141.
京公网安备 11010502046607号